GRO Biosciences

GRO Biosciences is leveraging breakthrough technologies from computational protein design and synthetic biology to develop best-in-class protein therapeutics with enhanced properties. The company has established multiple genomically recoded strains of bacteria that can incorporate non-standard amino acids into proteins to confer increased potency, stability, and targeted delivery. GRO Biosciences is applying its technology platform to develop improved protein therapeutics for diabetes, growth disorders and autoimmunity. The company, founded by Dr. George Church, is located at the Harvard Life Lab, a shared laboratory space for high-potential life sciences and biotechnology startups founded by Harvard faculty, alumni, students, and postdoctoral scholars.

A Change in Bacteria’s Genetic Code Holds Promise of Longer-Lasting Drugs

AUSTIN, Texas — By altering the genetic code in bacteria, researchers at The University of Texas at Austin have demonstrated a method to make therapeutic proteins more stable, an advance that would improve the drugs' effectiveness and convenience, leading to smaller and less frequent doses of medicine, lower health care costs and fewer side effects for patients with cancer and other diseases.

The results were published today in the journal Nature Biotechnology.

Many drugs commonly used to treat cancer and diseases of the immune system — including insulin, human growth hormone, interferon and monoclonal antibodies — can have a short active life span in the human body. That's because these drugs, which are proteins or chains of amino acids linked together by chemical bonds, contain the amino acid cysteine, which makes chemical bonds that break down in the presence of certain compounds found in human cells and blood.

Read the full post at UT News.